Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZE46-0134 in FLT3 and spliceosome mutated relapsed/refractory AML
NCT06366789Phase 1Recruiting
- Sponsor
- Lomond Therapeutics
- Start
- May 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of lomonitinib in acute myeloid leukemia (AML) (18 arms), sponsored by Lomond Therapeutics. Primary endpoint: Dose-Limiting Toxicities. Started May 2024; status: recruiting.
02
Drugs
lomonitinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06366789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366789.